pirbuterol has been researched along with Chronic Disease in 12 studies
pirbuterol: structure
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fifty-nine patients with severe chronic heart failure were given pirbuterol, a beta agonist with vasodilator and positive inotropic properties." | 9.05 | Treatment of chronic heart failure with pirbuterol: acute haemodynamic responses. ( Canepa-Anson, R; Carnie, J; Dawson, JR; Kuan, P; Poole-Wilson, PA; Reuben, SR; Sutton, GC; Warnes, C; Whitaker, NH, 1981) |
| "In 20 patients with severe congestive heart failure (CHF), we studied the effects of the beta-adrenergic agonist pirbuterol compared to placebo in both an acute double-blind randomized trial and after long-term treatment." | 9.05 | Acute and long-term hemodynamic effects of oral pirbuterol in patients with chronic severe congestive heart failure: randomized double-blind trial. ( Beller, GA; Bishop, HL; Carabello, BA; Gheorghiade, M; Grunwald, AM; Olukotun, AY; Pamelia, FX; Sirowatka, J; Taylor, CR; Watson, DD, 1983) |
| "We compared the initial and long-term effects of the beta-adrenergic agonist pirbuterol in 12 patients with chronic congestive heart failure." | 7.66 | Decreased lymphocyte beta-adrenergic-receptor density in patients with heart failure and tolerance to the beta-adrenergic agonist pirbuterol. ( Alexander, RW; Braunwald, E; Colucci, WS; Holman, BL; Konstam, MA; Mudge, GH; Rude, RE; Williams, GH; Wynne, J, 1981) |
| "Pirbuterol hydrochloride, an orally effective beta-adrenergic agonist, improves hemodynamic abnormalities in patients with congestive heart failure, but its effects on myocardial oxygen consumption (MVO2) and coronary blood flow have not been characterized." | 7.66 | Acute effects of oral pirbuterol on myocardial oxygen metabolism and systemic hemodynamics in chronic congestive heart failure. ( Brown, EJ; Colucci, WS; Grossman, W; Lorell, BH; Mudge, GH; Rude, RE; Taylor, CR; Turi, Z, 1981) |
| " To assess the adequacy of 20 mg of PB, the dose-response relations of cardiocirculatory effects to 10, 15, 20 and 30 mg of PB were compared in seven of the above patients and nine other patients." | 6.65 | Pirbuterol, an oral beta-adrenergic receptor agonist, in the treatment of chronic cardiac failure. ( Andrews, V; Janicki, JS; Likoff, M; Reichek, N; Weber, KT, 1982) |
| "Oral amrinone or pirbuterol were given in random order to each of 13 patients, on successive days, and oral isosorbide dinitrate was added after two-and-a-half hours." | 6.65 | Acute haemodynamic comparison of amrinone and pirbuterol in chronic heart failure. Additional effects of isosorbide dinitrate. ( Bayliss, J; Canepa-Anson, R; Norell, M; Poole-Wilson, PA; Reuben, SR; Sutton, GC, 1983) |
| "Fifty-nine patients with severe chronic heart failure were given pirbuterol, a beta agonist with vasodilator and positive inotropic properties." | 5.05 | Treatment of chronic heart failure with pirbuterol: acute haemodynamic responses. ( Canepa-Anson, R; Carnie, J; Dawson, JR; Kuan, P; Poole-Wilson, PA; Reuben, SR; Sutton, GC; Warnes, C; Whitaker, NH, 1981) |
| "In 20 patients with severe congestive heart failure (CHF), we studied the effects of the beta-adrenergic agonist pirbuterol compared to placebo in both an acute double-blind randomized trial and after long-term treatment." | 5.05 | Acute and long-term hemodynamic effects of oral pirbuterol in patients with chronic severe congestive heart failure: randomized double-blind trial. ( Beller, GA; Bishop, HL; Carabello, BA; Gheorghiade, M; Grunwald, AM; Olukotun, AY; Pamelia, FX; Sirowatka, J; Taylor, CR; Watson, DD, 1983) |
| "We compared the initial and long-term effects of the beta-adrenergic agonist pirbuterol in 12 patients with chronic congestive heart failure." | 3.66 | Decreased lymphocyte beta-adrenergic-receptor density in patients with heart failure and tolerance to the beta-adrenergic agonist pirbuterol. ( Alexander, RW; Braunwald, E; Colucci, WS; Holman, BL; Konstam, MA; Mudge, GH; Rude, RE; Williams, GH; Wynne, J, 1981) |
| "Pirbuterol hydrochloride, an orally effective beta-adrenergic agonist, improves hemodynamic abnormalities in patients with congestive heart failure, but its effects on myocardial oxygen consumption (MVO2) and coronary blood flow have not been characterized." | 3.66 | Acute effects of oral pirbuterol on myocardial oxygen metabolism and systemic hemodynamics in chronic congestive heart failure. ( Brown, EJ; Colucci, WS; Grossman, W; Lorell, BH; Mudge, GH; Rude, RE; Taylor, CR; Turi, Z, 1981) |
| " To assess the adequacy of 20 mg of PB, the dose-response relations of cardiocirculatory effects to 10, 15, 20 and 30 mg of PB were compared in seven of the above patients and nine other patients." | 2.65 | Pirbuterol, an oral beta-adrenergic receptor agonist, in the treatment of chronic cardiac failure. ( Andrews, V; Janicki, JS; Likoff, M; Reichek, N; Weber, KT, 1982) |
| "Oral amrinone or pirbuterol were given in random order to each of 13 patients, on successive days, and oral isosorbide dinitrate was added after two-and-a-half hours." | 2.65 | Acute haemodynamic comparison of amrinone and pirbuterol in chronic heart failure. Additional effects of isosorbide dinitrate. ( Bayliss, J; Canepa-Anson, R; Norell, M; Poole-Wilson, PA; Reuben, SR; Sutton, GC, 1983) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 12 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dawson, JR | 1 |
| Canepa-Anson, R | 2 |
| Kuan, P | 1 |
| Whitaker, NH | 1 |
| Carnie, J | 1 |
| Warnes, C | 1 |
| Reuben, SR | 2 |
| Poole-Wilson, PA | 2 |
| Sutton, GC | 2 |
| Colucci, WS | 2 |
| Alexander, RW | 1 |
| Williams, GH | 1 |
| Rude, RE | 2 |
| Holman, BL | 1 |
| Konstam, MA | 1 |
| Wynne, J | 1 |
| Mudge, GH | 2 |
| Braunwald, E | 1 |
| Weber, KT | 1 |
| Andrews, V | 1 |
| Janicki, JS | 1 |
| Likoff, M | 1 |
| Reichek, N | 1 |
| Bijak, A | 1 |
| Czołpiński, T | 1 |
| Winter, RJ | 1 |
| Langford, JA | 1 |
| Rudd, RM | 1 |
| Pamelia, FX | 1 |
| Gheorghiade, M | 1 |
| Beller, GA | 1 |
| Bishop, HL | 1 |
| Olukotun, AY | 1 |
| Taylor, CR | 3 |
| Watson, DD | 1 |
| Grunwald, AM | 1 |
| Sirowatka, J | 1 |
| Carabello, BA | 1 |
| Bayliss, J | 1 |
| Norell, M | 1 |
| Awan, NA | 2 |
| Needham, K | 1 |
| Evenson, MK | 2 |
| Mason, DT | 2 |
| Turi, Z | 1 |
| Brown, EJ | 1 |
| Lorell, BH | 1 |
| Grossman, W | 1 |
| Needham, KE | 1 |
| Evans, TO | 1 |
| Hermanovich, J | 1 |
| Amsterdam, E | 1 |
| Paterson, IC | 1 |
| Willey, RF | 1 |
| Grant, IW | 1 |
| Biernacki, W | 1 |
| Prince, K | 1 |
| Whyte, K | 1 |
| MacNee, W | 1 |
| Flenley, DC | 1 |
1 review available for pirbuterol and Chronic Disease
| Article | Year |
|---|---|
[New drugs with positive inotropic action].
Topics: Adrenergic beta-Agonists; Albuterol; Aminopyridines; Amrinone; Cardiotonic Agents; Chronic Disease; | 1982 |
7 trials available for pirbuterol and Chronic Disease
| Article | Year |
|---|---|
Treatment of chronic heart failure with pirbuterol: acute haemodynamic responses.
Topics: Administration, Oral; Adrenergic beta-Agonists; Adult; Aged; Chronic Disease; Ethanolamines; Female; | 1981 |
Pirbuterol, an oral beta-adrenergic receptor agonist, in the treatment of chronic cardiac failure.
Topics: Adrenergic beta-Agonists; Adult; Aged; Arrhythmias, Cardiac; Chronic Disease; Dose-Response Relation | 1982 |
Effects of oral and inhaled salbutamol and oral pirbuterol on right and left ventricular function in chronic bronchitis.
Topics: Administration, Intranasal; Administration, Oral; Adrenergic beta-Agonists; Albuterol; Bronchitis; C | 1984 |
Acute and long-term hemodynamic effects of oral pirbuterol in patients with chronic severe congestive heart failure: randomized double-blind trial.
Topics: Administration, Oral; Adult; Aged; Bronchodilator Agents; Chronic Disease; Clinical Trials as Topic; | 1983 |
Acute haemodynamic comparison of amrinone and pirbuterol in chronic heart failure. Additional effects of isosorbide dinitrate.
Topics: Adult; Aged; Aminopyridines; Amrinone; Cardiotonic Agents; Chronic Disease; Drug Therapy, Combinatio | 1983 |
Effects of prolonged administration of pirbuterol by mouth in chronic asthma.
Topics: Administration, Oral; Adolescent; Adrenergic beta-Agonists; Adult; Aged; Asthma; Chronic Disease; Cl | 1977 |
The effect of six months of daily treatment with the beta-2 agonist oral pirbuterol on pulmonary hemodynamics in patients with chronic hypoxic cor pulmonale receiving long-term oxygen therapy.
Topics: Adrenergic beta-Agonists; Aged; Bronchodilator Agents; Chronic Disease; Combined Modality Therapy; D | 1989 |
4 other studies available for pirbuterol and Chronic Disease
| Article | Year |
|---|---|
Decreased lymphocyte beta-adrenergic-receptor density in patients with heart failure and tolerance to the beta-adrenergic agonist pirbuterol.
Topics: Adrenergic beta-Agonists; Adult; Aged; Blood Pressure; Chronic Disease; Drug Tolerance; Ethanolamine | 1981 |
Management of severe chronic CHF with oral pirbuterol.
Topics: Cardiac Catheterization; Cardiac Output; Cardiotonic Agents; Chronic Disease; Ethanolamines; Heart F | 1981 |
Acute effects of oral pirbuterol on myocardial oxygen metabolism and systemic hemodynamics in chronic congestive heart failure.
Topics: Adult; Aged; Blood Pressure; Cardiac Output; Chronic Disease; Coronary Disease; Ethanolamines; Heart | 1981 |
Hemodynamic effects of oral pirbuterol in chronic severe congestive heart failure.
Topics: Adult; Aged; Blood Pressure; Cardiac Output; Cardiotonic Agents; Chronic Disease; Ethanolamines; Fem | 1981 |